This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Genor Biopharma Holdings 관리

관리 기준 확인 1/4

주요 정보

Feng Guo

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	2.4yrs
CEO 소유권	0.3%
경영진 평균 재임 기간	2.3yrs
이사회 평균 재임 기간	1.1yrs

최근 관리 업데이트

Recent updates

CEO

Feng Guo (52 yo)

2.4yrs

테뉴어

Dr. Feng Guo Ph D., serves as Chairman of the Board for Genor BioPharma Co., Ltd. since November 2021.He serves as Chairman at Genor Biopharma Holdings Limited since November 02, 2021. Dr. Guo has been th...

리더십 팀

이름	위치	테뉴어	보상	소유권
Feng Guo	CEO & Chairman	2.4yrs	데이터 없음	0.29% CN¥ 3.6m
Qibin Liang	Chief Technology Officer	1.7yrs	데이터 없음	데이터 없음
Shuhua Han	Chief Scientist	1.7yrs	데이터 없음	데이터 없음
Xiaojing Zhu	Vice President of Human Resources	no data	데이터 없음	데이터 없음
Tong Li	Chief Medical Officer	2.1yrs	데이터 없음	데이터 없음
Cheery Chen	Chief Regulatory Officer	1.7yrs	데이터 없음	데이터 없음
Tak Wai Ip	Company Secretary	less than a year	데이터 없음	데이터 없음
Huiyang Cheng	Vice President of Global Strategy	2.8yrs	데이터 없음	데이터 없음
Jun Lin	Vice President of Quality Analysis	2.7yrs	데이터 없음	데이터 없음
Yao Chen	Vice President of Regulatory Affairs	3.2yrs	데이터 없음	데이터 없음
Qingtang Duan	General Manager of Yuxi Genor	3.1yrs	데이터 없음	데이터 없음
Chengyi Weng	Vice President of Finance	no data	데이터 없음	데이터 없음

2.3yrs

평균 재임 기간

48yo

평균 연령

경험이 풍부한 관리: 6998's management team is considered experienced (2.3 years average tenure).

이사회 구성원

이름	위치	테뉴어	보상	소유권
Feng Guo	CEO & Chairman	2.4yrs	데이터 없음	0.29% CN¥ 3.6m
David J. Kerr	Member of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음
Leonard B. Saltz	Member of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음
Alex A. Adjei	Member of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음
Wen Chen	Independent Non-Executive Director	2.3yrs	데이터 없음	데이터 없음
Yu Chen	Non-Executive Director	3.8yrs	데이터 없음	데이터 없음
Edwin Fung	Independent Non-Executive Director	2.3yrs	데이터 없음	데이터 없음
Honghao Zhou	Independent Non-Executive Director	2yrs	데이터 없음	데이터 없음
Dong Lyu	Non Executive Director	less than a year	데이터 없음	데이터 없음
Zhijian Chen	Chairman of Scientific Advisory Board	1.3yrs	데이터 없음	데이터 없음
Yangxin Fu	Member of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음
John F. Seymour	Member of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음

1.1yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 이사회: 6998's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.

This company listing is no longer active

Genor Biopharma Holdings 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Genor Biopharma Holdings Limited Announces Management Changes with Effect from July 29, 2022

Genor Biopharma Holdings Limited Announces Executive Changes

Less than half of directors are independent

Genor Biopharma Holdings Limited Announces Resignation of Zhou Joe Xin Hua as Executive Director and President

Recent updates

Genor Biopharma Holdings Limited Announces Updates on New Product Application Approval of Geptanolimab (GB226) for the Treatment of Relapsed/Refractory Permitting T-Cell Lymphoma

Genor Biopharma Holdings Limited Announces Launch of Phase I/II Clinical Trial of GB263T in China

Genor Biopharma Holdings Limited Announces Launch of Phase I/Ii Clinical Trial Ofgb261 in China

Genor Biopharma Holdings Limited to Report First Half, 2022 Results on Aug 30, 2022

Genor Biopharma Holdings Limited Announces Management Changes with Effect from July 29, 2022

Genor Biopharma Holdings Limited Announces Executive Changes

Genor Biopharma Holdings Limited Obtains Investigational New Drug Approval from the National Medical Products Administration

Genor Biopharma Holdings Limited Announces National Medical Products Administration Grants New Approval for Phase I/II Clinical Trials of GB261

Genor Biopharma Holdings Limited Announces National Medical Products Administration Grants New Approval for Phase I/II Clinical Trials of GB261

Genor Biopharma Holdings Limited Announces First Patient Dosed in the First-In-Humanclinical Trial of GB263T

Less than half of directors are independent

Genor Biopharma Holdings Limited Announces Resignation of Zhou Joe Xin Hua as Executive Director and President

Genor Biopharma Holdings Limited Announces First-In-Human Clinical Trial of GB263T Approval by the Bellberry Human Research Ethics Committee

Genor Biopharma Holdings Limited Announces National Medical Products Administration Grants New Drug Application Approval for GB242 (Infliximab)

Genor Biopharma Holdings Limited Announces First Patient Enrolled in the Phase III Clinical Trial of Gb491 in China

JHBP (CY) Holdings Limited Receives Investigational New Drug Approval for GB492 by National Medical Products Administration

Non-Executive Director has left the company

Full year 2020 earnings released: CN¥12.36 loss per share (vs CN¥0.94 loss in FY 2019)

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령